NCT01409733Unknown1 期
TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Proportion of patients completing scheduled treatment plan
研究概览
简要总结
The Aim is to evaluate safety and efficacy of TACE with doxorubicin-loaded DC beads in melanoma patients with liver metastasis. This is a pilot study with the aim of recruiting 20 patients, this is a feasibility study. the patients profile is patients with stage IV Melanoma with liver metastases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with unresectable, measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST and EASL criteria (2D/3D-EASL) or MRI (Extent of Necrosis)
- •Patients ≥ 18 years of age, > 35kg, of any race or sex, who have histological or radiological proof of melanoma to the liver
- •ECOG performance status <
- •Patient chooses to participate and has signed the informed consent document.
- •Patients with unilobar disease who can be treated superselectively in a single session or patients with bilobar disease who can have both lobes able to be treated within 3 - 4 weeks in separate sessions.
- •Patients with patent main portal vein.
- •Ocular melanoma is allowed.
- •Patients with clinically and radiologically stable brain metastasis from melanoma can be included.
- •Patients with liver dominant disease (>50% overall tumor burden).
- •Prior systemic therapy for metastatic disease is allowed.
- •Non-pregnant with an acceptable contraception in premenopausal women and fertile men.
- •Hematological function: ANC ≥1.5 x 109/L, platelets ≥ 75 x 109/L, INR<1.3 (patients on therapeutic anticoagulants are not eligible).
- •Adequate renal function: Creatinine ≤2.0mg/dl and GFR >
- •Adequate liver function: total bilirubin ≤ 2.5 mg/dl, ALT, AST ≤ 5 times ULN, albumin ≥ 2.5mg/dl.
- •All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above
排除标准
- •Women who are pregnant or breast feeding.
- •Patients eligible for curative treatment such as resection or radiofrequency ablation.
- •Active bacterial, viral or fungal infection within 72 hours of study entry.
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 5 years prior to study entry.
- •Contraindication to hepatic artery embolization procedures:
- •Severe peripheral vascular disease precluding catheterization.
- •Large shunt as determined by the investigator (pretesting with TcMAA not required) at the time of first angiogram.
- •Hepatofugal blood flow.
- •Main portal vein occlusion (e.g. thrombus or tumor).
- •Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment.
- •Allergy to contrast media that cannot be managed with standard care (e.g. steroids), making magnetic resonance imaging (MRI) or computed tomography (CT) contraindicated.
- •Advanced liver disease (> 80% liver replacement).
- •Other significant medical or surgical condition, or any medication or treatment that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation.
- •Ongoing systemic cancer treatment.
- •Any contraindication for Doxorubicin administration:
- •WBC <3000 cells/mm3
- •Neutrophils <1500 cells/mm3
- •Deficient cardiac function defined as a LVEF of <50% normal
- •Allergy to Doxorubicin.
结局指标
主要结局
Proportion of patients completing scheduled treatment plan
时间窗: 12 months
Safety: Adverse Events Efficacy: Response to Treatment
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From MelanomaStage IV MelanomaNCT01010984Robert C. Martin20
已完成
2 期
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead EmbolisationPrimary Liver CancerNCT00261378Boston Scientific Corporation212
已完成
不适用
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinomaNeoplasmsKCT0002996Seoul National University Hospital30
终止
2 期
Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical ProstatectomyProstate CancerNCT04423913Centre Hospitalier Universitaire de Nīmes12
Unknown
3 期
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT04229355Guangxi Medical University90